LYPD6

Summary

LYPD6 (LY6/PLAUR domain containing 6, HGNC:28751) is a protein-coding gene on chromosome 2q23.2, encoding Ly6/PLAUR domain-containing protein 6 (Q86Y78). Acts as a modulator of nicotinic acetylcholine receptors (nAChRs) function in the brain.

Members of the LY6 protein family (see SLURP1; MIM 606119), such as LYPD6, have at least one 80-amino acid LU domain that contains 10 conserved cysteines with a defined disulfide-bonding pattern (Zhang et al., 2010 [PubMed 19653121]).

Source: NCBI Gene 130574 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 26 total
• MANE Select transcript: NM_194317

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28751
Approved symbol	LYPD6
Name	LY6/PLAUR domain containing 6
Location	2q23.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC52057
Ensembl gene	ENSG00000187123
Ensembl biotype	protein_coding
OMIM	613359
Entrez	130574

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 nonsense_mediated_decay

ENST00000334166, ENST00000392854, ENST00000409381, ENST00000414420, ENST00000418762, ENST00000651933, ENST00000880626, ENST00000946762

RefSeq mRNA: 2 — MANE Select: NM_194317 NM_001195685, NM_194317

CCDS: CCDS2188

Canonical transcript exons

ENST00000334166 — 5 exons

Exon	Start	End
ENSE00001337511	149449049	149449147
ENSE00001337517	149437638	149437826
ENSE00001513370	149330587	149330722
ENSE00001916516	149470683	149474138
ENSE00003468252	149468645	149468775

Expression profiles

Bgee: expression breadth ubiquitous, 174 present calls, max score 96.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.5417 / max 59.2212, expressed in 1008 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
23019	4.5417	1008

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	96.20	gold quality
secondary oocyte	CL:0000655	91.05	gold quality
oocyte	CL:0000023	87.86	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.79	gold quality
gall bladder	UBERON:0002110	82.13	gold quality
ganglionic eminence	UBERON:0004023	81.76	gold quality
buccal mucosa cell	CL:0002336	79.03	gold quality
stromal cell of endometrium	CL:0002255	77.37	gold quality
pancreatic ductal cell	CL:0002079	77.27	silver quality
ventricular zone	UBERON:0003053	75.12	gold quality
left testis	UBERON:0004533	74.90	gold quality
prefrontal cortex	UBERON:0000451	74.81	gold quality
anterior cingulate cortex	UBERON:0009835	74.81	gold quality
right testis	UBERON:0004534	74.48	gold quality
testis	UBERON:0000473	74.14	gold quality
hypothalamus	UBERON:0001898	73.27	gold quality
placenta	UBERON:0001987	73.23	gold quality
oviduct epithelium	UBERON:0004804	73.01	gold quality
tibialis anterior	UBERON:0001385	72.65	silver quality
amygdala	UBERON:0001876	72.00	gold quality
caudate nucleus	UBERON:0001873	71.79	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	71.78	gold quality
neocortex	UBERON:0001950	71.55	gold quality
right frontal lobe	UBERON:0002810	71.39	gold quality
frontal cortex	UBERON:0001870	70.91	gold quality
cortical plate	UBERON:0005343	70.55	gold quality
Brodmann (1909) area 9	UBERON:0013540	70.33	gold quality
cerebral cortex	UBERON:0000956	69.68	gold quality
ileal mucosa	UBERON:0000331	69.57	silver quality
tibial nerve	UBERON:0001323	69.40	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7008	yes	53.48
E-ANND-3	no	3.67

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

151 targeting LYPD6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-570-3P	99.96	72.41	4910
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-95-5P	99.89	72.17	3973

Literature-anchored findings (GeneRIF, showing 5)

• The cloning and characterization of a novel human LU domain containing gene, LYPD6, isolated from human testis cDNA library, is reported. (PMID:19653121)
• Lypd6 appears to control Lrp6 activation specifically in membrane rafts, which is essential for downstream signaling. (PMID:23987510)
• the Lynx protein Lypd6 binds to nAChRs in human brain extracts, and that recombinant Lypd6 decreases nicotine-induced ERK phosphorylation (PMID:27344019)
• Results indicate the key role in the interaction of LY6/PLAUR domain containing 6 (LYPD6) with LDL receptor related protein 6 (LRP6). (PMID:30069874)
• Structural Diversity and Dynamics of Human Three-Finger Proteins Acting on Nicotinic Acetylcholine Receptors. (PMID:33019770)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lypd6	ENSDARG00000004307
mus_musculus	Lypd6	ENSMUSG00000050447
rattus_norvegicus	Lypd6	ENSRNOG00000085812

Paralogs (1): LYPD6B (ENSG00000150556)

Protein

Protein identifiers

Ly6/PLAUR domain-containing protein 6 — Q86Y78 (reviewed: Q86Y78)

All UniProt accessions (2): C9IYE7, Q86Y78

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a modulator of nicotinic acetylcholine receptors (nAChRs) function in the brain. Inhibits nicotine-induced Ca(2+) influx through nAChRs. In vitro, specifically inhibits alpha-3:beta-4 and alpha-7 nAChR currents in an allosteric manner. Acts as a positive regulator of Wnt/beta-catenin signaling.

Subunit / interactions. Interacts with nicotinic acetylcholine receptors (nAChRs) including CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2 and CHRNB4. Interacts (via NxI motif) with LRP6.

Subcellular location. Secreted. Cytoplasm. Cell membrane. Synapse. Synaptosome. Membrane raft. Cell projection. Dendrite. Perikaryon.

Tissue specificity. Detected in the temporal cortex (at protein level). Ubiquitous. Highly expressed in brain and heart.

Domain organisation. The UPAR/Ly6 domain is sufficient for inhibiting alpha-3:beta-4 and alpha-7-dependent nAChR currents.

Isoforms (2)

UniProt ID	Names	Canonical?
Q86Y78-1	1	yes
Q86Y78-2	2

RefSeq proteins (2): NP_001182614, NP_919298* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR039457	LYPD6-like	Family
IPR045860	Snake_toxin-like_sf	Homologous_superfamily

Pfam: PF16975

UniProt features (33 total): strand 9, disulfide bond 6, mutagenesis site 4, splice variant 2, helix 2, glycosylation site 2, signal peptide 1, chain 1, propeptide 1, sequence conflict 1, domain 1, turn 1, short sequence motif 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6GBI	X-RAY DIFFRACTION	1.25
6IB6	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86Y78-F1	86.14	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 147

Disulfide bonds (6): 70–96, 102–121, 107–118, 122–127, 49–77, 52–61

Glycosylation sites (2): 134, 147

Mutagenesis-validated functional residues (4):

Position	Phenotype
83–92	able to bind to lrp6.
88	abolishes binding to lrp6.
90	severely reduces binding to lrp6.
111	increased binding to lrp6.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 121 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GOBP_FOREBRAIN_DEVELOPMENT, GOBP_CELL_CELL_SIGNALING, GOBP_FOREBRAIN_GENERATION_OF_NEURONS, CTAGGAA_MIR384, IRF7_01, GOBP_CEREBRAL_CORTEX_NEURON_DIFFERENTIATION, GOBP_REGULATION_OF_SYNAPTIC_PLASTICITY, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, GOBP_HIPPOCAMPUS_DEVELOPMENT, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, BILD_E2F3_ONCOGENIC_SIGNATURE

GO Biological Process (7): visual perception (GO:0007601), pyramidal neuron differentiation (GO:0021859), regulation of synaptic plasticity (GO:0048167), positive regulation of canonical Wnt signaling pathway (GO:0090263), hippocampal interneuron differentiation (GO:0097410), nervous system development (GO:0007399), neuron differentiation (GO:0030182)

GO Molecular Function (3): acetylcholine receptor inhibitor activity (GO:0030550), protein binding (GO:0005515), acetylcholine receptor regulator activity (GO:0030548)

GO Cellular Component (11): extracellular region (GO:0005576), cytoplasm (GO:0005737), plasma membrane (GO:0005886), dendrite (GO:0030425), perikaryon (GO:0043204), membrane raft (GO:0045121), synapse (GO:0045202), side of membrane (GO:0098552), membrane (GO:0016020), cell projection (GO:0042995), neuron projection (GO:0043005)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
acetylcholine receptor activity	2
membrane	2
sensory perception of light stimulus	1
central nervous system neuron differentiation	1
modulation of chemical synaptic transmission	1
regulation of biological quality	1
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
hippocampus development	1
cerebral cortex neuron differentiation	1
system development	1
cell differentiation	1
generation of neurons	1
signaling receptor inhibitor activity	1
acetylcholine receptor regulator activity	1
binding	1
neurotransmitter receptor regulator activity	1
intracellular anatomical structure	1
cell periphery	1
neuron projection	1
dendritic tree	1
neuronal cell body	1
membrane microdomain	1
cell junction	1
leaflet of membrane bilayer	1
plasma membrane bounded cell projection	1

Protein interactions and networks

STRING

1353 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LYPD6	SLURP1	P55000	953
LYPD6	LRP6	O75581	815
LYPD6	LYNX1	P0DP58	778
LYPD6	FZD8	Q9H461	720
LYPD6	LY6H	O94772	712
LYPD6	INSYN2B	A6NMK8	602
LYPD6	LY6K	Q17RY6	595
LYPD6	PATE4	P0C8F1	477
LYPD6	GPIHBP1	Q8IV16	476
LYPD6	LRRC34	Q8IZ02	475
LYPD6	ACRV1	P26436	474
LYPD6	TMEM174	Q8WUU8	457
LYPD6	CCDC175	P0C221	450
LYPD6	PATE2	Q6UY27	447
LYPD6	ZNF513	Q8N8E2	433

IntAct

10 interactions, top by confidence:

A	B	Type	Score
LYPD6	SS18L2	psi-mi:“MI:0915”(physical association)	0.560
LYPD6	PLXNB2	psi-mi:“MI:0914”(association)	0.530
LYPD6	CHRNB2	psi-mi:“MI:0914”(association)	0.350
LYPD6	Chrna4	psi-mi:“MI:0914”(association)	0.350
SS18L2	LYPD6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (71): ATP1A3 (Affinity Capture-MS), LPGAT1 (Affinity Capture-MS), CELSR1 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), PLXNB2 (Affinity Capture-MS), DNM2 (Affinity Capture-MS), DNM1 (Affinity Capture-MS), DNM3 (Affinity Capture-MS), CKAP4 (Affinity Capture-MS), TMX1 (Affinity Capture-MS), SOAT1 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), SIDT2 (Affinity Capture-MS), TMEM68 (Affinity Capture-MS), PTPN1 (Affinity Capture-MS)

ESM2 similar proteins: A6NCL2, D3ZTT2, O19131, O46655, O70280, P01177, P01178, P01179, P01180, P01183, P01185, P01186, P03973, P13389, P19438, P22298, P22934, P25118, P35454, P35455, P50555, P58658, P58659, Q02509, Q14AE4, Q32LD3, Q3URS3, Q5T700, Q68US5, Q6UWE3, Q6UWL2, Q6V9X0, Q6WN34, Q76LW6, Q86Y78, Q8BPP5, Q8BVP6, Q8N6Q3, Q8VEA6, Q8WXA2

Diamond homologs: D3ZTT2, Q66IA6, Q86Y78, Q8BPP5, Q8NI32, Q9D7F2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

26 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1894 predictions. Top by Δscore:

Variant	Effect	Δscore
2:149437827:G:GG	donor_gain	1.0000
2:149449047:A:AG	acceptor_gain	1.0000
2:149449048:G:GG	acceptor_gain	1.0000
2:149449048:GCC:G	acceptor_gain	1.0000
2:149449145:GAGG:G	donor_loss	1.0000
2:149449146:AG:A	donor_loss	1.0000
2:149449147:GGTAA:G	donor_loss	1.0000
2:149449148:G:C	donor_loss	1.0000
2:149449149:T:A	donor_loss	1.0000
2:149335308:ATCCC:A	donor_gain	0.9900
2:149411396:G:GT	donor_gain	0.9900
2:149411397:A:T	donor_gain	0.9900
2:149437632:TTTCA:T	acceptor_loss	0.9900
2:149437633:TTCA:T	acceptor_loss	0.9900
2:149437634:TCA:T	acceptor_loss	0.9900
2:149437636:A:C	acceptor_loss	0.9900
2:149437823:TCAAG:T	donor_loss	0.9900
2:149437824:CAAG:C	donor_loss	0.9900
2:149437825:AAG:A	donor_loss	0.9900
2:149437826:AG:A	donor_loss	0.9900
2:149437827:G:A	donor_loss	0.9900
2:149437828:TA:T	donor_loss	0.9900
2:149437829:A:C	donor_loss	0.9900
2:149449046:TA:T	acceptor_loss	0.9900
2:149449048:G:GT	acceptor_loss	0.9900
2:149449048:GC:G	acceptor_gain	0.9900
2:149449048:GCCAC:G	acceptor_gain	0.9900
2:149468796:GACC:G	donor_gain	0.9900
2:149468797:ACCA:A	donor_gain	0.9900
2:149330200:A:T	donor_gain	0.9800

AlphaMissense

1097 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:149449079:T:G	F50C	1.000
2:149468709:A:C	K94N	1.000
2:149468709:A:T	K94N	1.000
2:149449074:A:C	K48N	0.999
2:149449074:A:T	K48N	0.999
2:149449075:T:A	C49S	0.999
2:149449076:G:C	C49S	0.999
2:149449078:T:C	F50L	0.999
2:149449079:T:C	F50S	0.999
2:149449080:C:A	F50L	0.999
2:149449080:C:G	F50L	0.999
2:149449085:G:A	C52Y	0.999
2:149449104:T:A	N58K	0.999
2:149449104:T:G	N58K	0.999
2:149449111:T:A	C61S	0.999
2:149449111:T:C	C61R	0.999
2:149449112:G:C	C61S	0.999
2:149449113:C:G	C61W	0.999
2:149449116:C:A	N62K	0.999
2:149449116:C:G	N62K	0.999
2:149449122:G:C	W64C	0.999
2:149449122:G:T	W64C	0.999
2:149468656:T:A	C77S	0.999
2:149468657:G:C	C77S	0.999
2:149468658:C:G	C77W	0.999
2:149468708:A:T	K94I	0.999
2:149468713:T:A	C96S	0.999
2:149468714:G:C	C96S	0.999
2:149470718:C:A	N128K	0.999
2:149470718:C:G	N128K	0.999

dbSNP variants (sampled 300 via entrez): RS1000001449 (2:149435590 C>A,G,T), RS1000007931 (2:149393222 T>G), RS1000017107 (2:149453677 T>G), RS1000024322 (2:149390677 G>C), RS1000025421 (2:149372385 A>C,G), RS1000079869 (2:149423646 T>C), RS1000081644 (2:149364771 C>A,T), RS1000083497 (2:149408147 G>T), RS1000096298 (2:149335881 A>G), RS1000106828 (2:149365032 G>A), RS1000120594 (2:149377154 C>A), RS1000138236 (2:149366188 T>C), RS1000168 (2:149484557 G>A,C), RS1000168414 (2:149472315 C>T), RS1000179569 (2:149356421 C>T)

Disease associations

OMIM: gene MIM:613359 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003518_13	Daytime sleep phenotypes	4.000000e-06
GCST006631_6	Nicotine dependence and major depression (severity of comorbidity)	6.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement
EFO:0007006	depressive symptom measurement
EFO:0009262	nicotine dependence symptom count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	5
sodium arsenite	decreases expression, increases abundance, increases expression	3
potassium chromate(VI)	increases expression, affects cotreatment, decreases expression	2
Resveratrol	decreases expression, affects cotreatment, increases expression	2
Benzo(a)pyrene	decreases methylation, increases expression, increases methylation, affects methylation	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
sulforaphane	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
benzo(e)pyrene	decreases methylation	1
nickel sulfate	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
chromium hexavalent ion	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Arsenic	increases abundance, decreases expression	1
Coumestrol	affects cotreatment, increases expression	1
Methapyrilene	decreases methylation	1
Pesticides	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome